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http://dx.doi.org/10.1016/j.bgm.201Abstract Hypoxia is an intricate microenvironment associated with aggressiveness and che-
moresistance of a variety of solid tumors. Hypoxia-inducible factors (HIFs) regulate down-
stream target genes that render cancer cells capacity to adapt to the hostile, low-oxygen
stress for survival. HIF has been estimated to regulate more than 5% of total human genes.
The HIF-regulated gene network has been shown to be associated with resistance to chemo-
therapy, metastasis, tumor recurrence, and reduced overall survival rate. With the increasing
findings that microRNAs (miRNAs) are aberrantly expressed under hypoxia, which participate
positively or negatively in regulating hypoxia-related genes, the signaling pathway of hypoxia
becomes more and more complicated. Based on the roles of miRNAs in tumor development and
drug resistance, the potential of targeting miRNAs as a therapeutic regimen has been empha-
sized recently. Therefore, understanding the regulation and functions of miRNAs in cancer
cells will provide us with useful information for designing more efficacious treatment regi-
mens. In this article, we will review the biological kinship of hypoxia and hypoxia-regulated
miRNAs in cancer malignancy and drug resistance.
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Cancer is a major public health problem and its treatment
creates a huge financial burden for patients. The reasons
contributing to tumor development and treatment failure
are related to mutations of various oncogenes and tumor
suppressor genes or to a continuous change of microenvi-
ronment. Despite the increasing understanding of mecha-
nisms responsible for tumorigenesis and advancement inrker Society. Published by Elsevier Taiwan LLC. All rights reserved.
2 W.-L. Liao et al.cancer therapy, the complex etiology of carcinogenesis
remains a major hurdle to cure patients efficiently. Thus, it
is critical to elucidate more information about cancer
biology.
MicroRNAs (miRNAs) are short, noncoding RNAs that
inhibit the expression of genes by causing either messenger
RNA (mRNA) degradation or protein translational repres-
sion.1,2 Since their discovery in 1993, miRNAs continue to be
at the center stage of the “noncoding RNA revolution”. So
far, miRNAs have been thought to regulate the expression of
most genes and consequently play critical roles in the coor-
dination of a wide variety of processes such as cell differ-
entiation, proliferation, death, and metabolism.3 Besides,
accumulating evidence has shown that miRNAs are associ-
ated with various steps of tumorigenesis,4 and altered
expression profiles of miRNAs in cancers indicate their po-
tential as biomarkers with clinicopathological features.5e8
Given the diverse roles of miRNAs in numerous aspects of
cancer biology, it is not surprising that they also play a role in
hypoxia, which is an essential feature of the neoplastic
microenvironment.Recently, a signatureofhypoxia-inducible
miRNAs has been identified.9 Notably, many hypoxia-induced
miRNAs are also overexpressed in human cancers, suggesting
that induction of these miRNAs may affect important target
genes involved in tumor survival, proliferation, vasculariza-
tion, or alteration of the response to chemotherapy. Herein,
we will summarize recent findings on hypoxia-associated
miRNAs and the impacts of these miRNAs and their
target genes on tumor malignancy and/or drug resistance.
Hypoxia, hypoxia-inducible factor, and cancer
malignancy
Regulation of hypoxia-inducible factor
Cancer malignancy is the most serious problem that causes
numerous deaths every year worldwide. Malignancy arises
from many factors such as uncontrolled growth of cancer
cells, abnormal metabolism, angiogenesis, metastasis, and
resistance to chemotherapy. Microenvironment is also an
important factor related to malignancy, and hypoxia is the
most common neoplastic microenvironment in solid tumors
in which oxygen concentration is reduced markedly. In
order to overcome hypoxic situation and acquire sufficient
oxygen, hypoxic cells activate numerous genes involved in
angiogenesis, glucose metabolism, cell proliferation, and
survival through transcriptional upregulation by hypoxia-
inducible factor (HIF). This adaptive response co-opted by
cancer cells usually results in further cancer progression or
drug resistance, which ultimately leads to patient mortal-
ity.10e14 The well-known HIF is a heterodimeric transcrip-
tion factor composed of one a subunit and one b subunit.
The a subunit has three isoforms: HIF-1a, HIF-2a, and HIF-
3a. HIF-1a is widely expressed in most tissues, but the
expression of HIF-2a is more restricted. In contrast to the
aforementioned HIFs, the expression and function of HIF-3a
are less clear. HIF activities are regulated by the induction
or stabilization of the a subunit, which is tightly regulated
by oxygen tension. HIF-1a is usually kept at a low level in
normoxic condition due to ubiquitination-dependent pro-
tein degradation. Oxygen-dependent prolyl hydroxylase(PHD) hydroxylates the proline residues (Pro402 and Pro564
in human HIF-1a) and promotes the recognition by von
HippeleLindau (VHL) protein, an E3 ligase. Ubiquitinated
HIF-a is then degraded by the 26S-proteasomal degradation
pathway.15,16 Under hypoxia, hydroxylation of HIF-a is
attenuated and HIF-a is stabilized (Fig. 1). In sharp contrast
to the a subunit, the b subunit of HIF, also called aryl hy-
drocarbon receptor nuclear translocator, is expressed
constitutively.
Metabolic alternation under hypoxia
Increased conversion of glucose to lactate has been regar-
ded as a critical cellular metabolic adaptation to hypoxia.
This reprogramming in metabolism has a causal impact on
tumor progression.17,18 Cancer cells have been found to
predominantly produce energy by a high rate of glycolysis
followed by lactate fermentation, rather than by oxidation
of pyruvate in mitochondria, the major way of producing
energy by normal cells (Fig. 2). The elevated glucose up-
take by cancer cells is due to an increased expression of
genes such as glucose transporters (Glut1 and Glut3) and
many glycolytic enzymes (hexokinase1, hexokinase2 (HK1
and HK2), glucosephosphate isomerase (GPI), aldolase A
(ALDA) and lactate dehydrogenase A (LDHA)) induced by
HIF-1a.19,20 However, the key point of switching mito-
chondrial phosphorylation to cytoplasmic glycolysis is the
suppression of pyruvate conversion to acetyl coenzyme A
(acetyl-CoA). Hypoxia induces the expression of pyruvate
dehydrogenase kinase-1 and kinase-3 (PDK1 and PDK3) in an
HIF-1- and HIF-2-dependent manner.21e23 PDK1 and PDK3
inactivate pyruvate dehydrogenase (PDH), an enzyme that
converts pyruvate to acetyl-CoA, which fuels the tricar-
boxylic acid cycle. Inhibition of PDH by PDK prevents
mitochondrial phosphorylation and facilitates cytosolic
glycolysis. Although the mechanism is not completely un-
derstood, the switch from oxidative phosphorylation to
aerobic glycolysis increases drug resistance. Indeed, upre-
gulation of PDK3 in colon cancer has been found to be
associated with drug resistance and early recurrence.24
Alteration in cell proliferation and apoptosis
Dysregulation of cell proliferation under hypoxia is a pivotal
cause of tumor malignancy. The PI3K/Akt/mTOR signaling
pathway has been demonstrated to participate in a variety
of cellular processes such as cell proliferation, migration,
and metabolism.25 A plethora of studies have provided
supportive evidence indicating that hypoxia induces the
PI3K/Akt/mTOR signaling pathway in a HIF-dependent
manner in a variety of cancer cells. All this evidence sug-
gests that HIF and the PI3K/Akt/mTOR signaling pathway
form a feed-forward loop under a hypoxic microenviron-
ment, which leads to tumor malignancy.26e28
Defective apoptosis and cell cycle have been found in
hypoxia. For most normal cells, the cell-cycle arrest and
apoptosis are induced under hypoxia in an HIF-dependent
manner. By contrast, tumor cells exert different responses
to hypoxia by activating antiapoptotic genes (e.g., Bcl2,
Bcl-xL, Mcl-1, NF-kB, and survivin) in an HIF-dependent
manner instead of activating proapoptotic genes.29,30
Figure 1 Regulation of HIF-1a protein under normoxia and hypoxia. HIF Z hypoxia-inducible factor; PHD Z prolyl hydroxylase;
VHL Z von HippeleLindau.
Figure 2 Schematic drawing showing hypoxia-mediated metabolic switch. Acetyl-CoA Z acetyl coenzyme A; HIF Z hypoxia-
inducible factor; PDH Z pyruvate dehydrogenase; PDK Z pyruvate dehydrogenase kinase; TCA Z tricarboxylic acid.
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Angiogenesis is defined as the formation of new blood
vessels from the pre-existing vasculature and has been
demonstrated to play essential roles in tumor growth, in-
vasion, and metastasis. It is well known that angiogenesis is
regulated by mediating angiogenic factors such as vascular
endothelial growth factor (VEGF). Tumor hypoxia is the
most well-studied stimulus for the induction of angiogen-
esis, and the involvement of HIF-1a in the regulation of
VEGF expression is well documented.31
Hypoxia, HIF, and drug resistance
To overcome the adversity of drug resistance occurring in
patients with advanced and inoperable cancer is always
deemed to be a difficult task. Three basic categories that
describe the cause of chemotherapy failure are as follows:
inadequate pharmacokinetic properties of a drug, intrinsic
factors such as adenosine triphosphate (ATP)-binding
cassette transport protein that affects drug efflux, and
extrinsic conditions that exist in the tumor microenviron-
ment, such as hypoxia. Intrinsic and extrinsic factors often
interact with each other to enhance drug resistance,
making the situation even more complicated. Hypoxia is a
hallmark of the neoplastic microenvironment and a well-
documented source of therapeutic failure in clinical
oncology. Contribution of HIFs to drug resistance has been
observed in a wide spectrum of solid tumor cells in vitro.
The multidrug resistance 1 (MDR1) gene, which encodes
a membrane-resident P-glycoprotein, is a member of the
ATP-binding cassette family and is reported to be upregu-
lated under hypoxia.32 As a drug efflux pump, upregulation
of MDR1 will lead to chemoresistance by pumping chemo-
therapeutic drugs. A significant correlation between the
expression of HIF-1a and upregulation of MDR1 has been
reported in colon cancer.33,34 MRP-1 (a multidrug-
resistance-associated protein), another ATP-binding
cassette transporter, has also been found to be relevant
to HIF-1a-mediated drug resistance.35e37
MiRNAs and cancer
Since the discovery of the first miRNA in 1993, the role of
miRNAs in gene regulation has been exploited, especially in
recent years.1,38 MiRNAs are small, 19e25 nucleotide non-
coding RNAs and act as negative regulators of gene
expression. Like a conventional protein-coding mRNA, pri-
mary miRNA transcripts are generated by RNA polymerase
II. Then in the nucleus, primary miRNA transcripts are
processed by an RNase III endonuclease, Drosha, to form
hairpin-containing precursor miRNAs. These hairpin-
containing precursor miRNAs are subsequently exported to
the cytoplasm by exportin 5. In the cytoplasm, precursor
miRNAs are then processed by Dicer to form mature miR-
NAs. Usually, mature miRNAs are incorporated into the
RNA-induced silencing complex and target specific se-
quences located in the 30 untranslated region of mRNA. This
perfect or imperfect base pairing will lead to an mRNA
cleavage or translational repression of the targeted
mRNA.39 It has been reported that miRNAs regulate most ofthe physiological and pathological cellular processes1 and
also influence numerous cancer-relevant processes such as
proliferation, cell-cycle control, apoptosis, differentiation,
migration, and metabolism.40 Some miRNAs are aberrantly
expressed due to genomic abnormalities or epigenetic
modification.41,42 The microarray expression profile from a
wide spectrum of cancer diseases has shown that aberrant
miRNAs are expressed in cancers.43e46 Importantly, mouse
models featuring miRNA overexpression or ablation have
demonstrated causal links between miRNAs and cancer
development, implying that miRNAs have the potential to
serve as biomarkers and putative therapeutic targets in
clinic.47,48
Although limited miRNA promoters were characterized
experimentally, several studies, which determined global
miRNA promoter architecture, showed their similarity to
promoters of protein-coding mRNA.49,50 Not surprisingly,
miRNA promoters are also replete with consensus binding
sites of transcription factors, and thus the expression of
specific subsets of miRNAs can be regulated by a hypoxia-
induced transcription factor in the context of cellular
hypoxia. These miRNAs regulated by hypoxic stress are
termed hypoxamirs.51,52 Recent evidence indicates that the
transcription of some hypoxamirs can be induced by HIF
through its binding to a hypoxia response element (HRE)
located in the promoter.53,54
Hypoxia and miRNAs
Hypoxia-regulated miRNAs
Despite myriads of reports demonstrating that altered
miRNA expression is a common phenomenon in human
cancer and correlated with malignancy or resistance to
conventional therapy, relatively few reports elucidate
mechanisms involving in this profile alteration. The pro-
posed mechanism described that dysregulated signal
transduction pathways, which in turn activate/repress the
transcription of miRNA genes, could be involved in cancer
progression.55 Although the microenvironment of tumors
also affects tumor pathogenesis and response to chemo-
therapy,56,57 relatively little is known about the abnormal
expression of miRNA in cancer cells, which is also regulated
by microenvironmental factors.
As mentioned above, hypoxia is an essential feature of
the neoplastic microenvironment. Thus, hypoxia-regulated
miRNAs (HRMs) are deemed to play some role in cancer
invasion or drug resistance. As such, cancer-associated
miRNA profiles should exhibit a hypoxic signature. Based
on this idea, Kulshreshtha and colleagues9 first used human
cancer cell lines to characterize miRNAs responding to ox-
ygen deprivation by microarray-based screening. Candi-
dates selected using the microarray data were confirmed by
Northern analysis or quantitative real-time polymerase
chain reaction to confirm the bona fide character of HRMs.
They showed experimental evidence that caspase activa-
tion is inhibited by several HRMs during hypoxia. Interest-
ingly, they further used programs such as TargetScan,
PicTar, and miRBase to predict that several HRMs can target
core components of apoptotic genes such as BAK1 (targeted
by miR-26), BIM (miR-24 and miR-181), BID (miR-23), and
Hypoxia-mediated miRNA in drug resistance 5caspase-7 (miR-23). This is the first hint that hypoxia may
represent a key “trigger” contributing to miRNA alteration
in tumors. This alteration may affect downstream target
genes that are involved in cell survival and apoptosis, which
cause malignancy and drug resistance.
Shortly after this pioneering study, several studies
demonstrating specific HRMs and their target genes have
been conducted, and the number of such reports is
increasing. From these published studies, we can find that
HRMs are classified into two groups: miRNAs that are
induced under hypoxia in an HIF-dependent pathway or
through an unclear mechanism, and miRNAs that are
reduced under hypoxia. Up- or downregulated miRNAs may
impact tumor malignancy or drug resistance according to
the target genes they affect. Here, we summarized some
published studies demonstrating that the target genes of
HRMs exert significant effects on tumor malignancy or drug
resistance (Table 1, Fig. 3).
MiR-103/107
Death-associated protein kinase (DAPK) is a metastasis
suppressor. The expression of DAPK has been reported to
inhibit metastasis of Lewis lung carcinoma by increasing
apoptosis of tumor cells.76 Kru¨ppel-like factor 4 (KLF4), a
zinc finger transcriptional factor, is maximally expressed inTable 1 Targets of hypoxia-regulated miRNAs and their functio
miRNA Effect of
hypoxia
miRNA
target(s)
Biological pr
miR-103/107 Upregulate DAPK, KLF4 Oncogenesis
miR-424 Upregulate CUL2 Angiogenesis
miR-20a Upregulate DUSP2 Proliferation
angiogenesis
miR-210 Upregulate ISCU1/2,
RAD52,
ephrinA3
Mitochondria
metabolism
DNA repair,
angiogenesis
miR-200b Upregulate PHD2 Angiogenesis
miR-200b Unknown PTPN12 Oncogenesis
miR-200b Downregulate Ets-1 Angiogenesis
miR-15b Downregulate VEGF Angiogenesis
miR-16 Downregulate VEGF Angiogenesis
miR-15b Unknown Bcl-2 Drug resistan
miR-16 Unknown Bcl-2 Drug resistan
miR-100 Downregulate FGFR3 Proliferation
miR-199a Downregulate HIF-1a,
Sirtuin1
Induction of
proapoptotic
genes, prolif
CUL Z cullin; DAPK Z death-associated protein kinase; DUSP Z dual
oncogene homolog 1; FGFR Z fibroblast growth factor receptor;
PHD Z prolyl hydroxylase; VEGF Z vascular endothelial growth factoepithelial cells of the gastrointestinal tract, skin, and
vascular endothelial cells. Downregulation of KLF4 protein
expression in the colon may contribute to cellular hyper-
proliferation and malignant transformation.77 Chen et al58
found that, in colorectal cancer, DAPK and KLF4 were tar-
gets of miR-103 and miR-107. High levels of miR-103/107
result in low expressions of DAPK and KLF4, which corre-
late with metastasis state and poor prognosis. In addition,
they also found that miR-103/107 levels were induced by
hypoxia, and meanwhile, DAPK and KLF4 were down-
regulated. This observation indicates that hypoxia-induced
miR-103/107 contributes to cancer migration and invasion.
MiR-424
Cullin 2 (CUL2) is a scaffold protein of the VHL protein
critical to the assembly of the ubiquitin ligase system. In
normoxia, HIF-1a is hydroxylated at two proline residues by
PHDs,78 then the hydroxylated HIF-1a is recognized by the
VHL protein, an E3 ligase that ubiquitinates HIF-1a, and
subjected to degradation by 26S-proteasome.15,16 Thus, the
level of HIF-1a is very low under normoxic condition. In
Ghosh et al’s59 study, they found that CUL2 is a target of
miR-424 and, under hypoxic conditions, the expression of
miR-424 is elevated, resulting in a decreased expression of
CUL2 in endothelial cells. The inhibition of CUL2nal roles.
ocess Resistance
to drug
Cell types Refs
Unknown Colorectal cancer 58
Unknown Endothelial cell 59
/ Unknown Endometriotic
stromal cell
60
l Unknown Most cell lines 61e66
Unknown Neuroblast cell 67
Gemcitabine Cholangiocarcinoma
cell
68
Unknown Endothelial cell 69
Unknown Nasopharyngeal
carcinoma cell
70
Unknown Nasopharyngeal
carcinoma cell,
anaplastic large
cell lymphoma
70,71
ce Vincristine,
doxorubicin
Gastric cancer cell 72
ce Etoposide,
cisplatin
Gastric cancer cell 72
Unknown Bladder cancer cell 73
eration
Unknown Cardiac myocytes/
non-small-cell
lung cancer
74,75
-specificity phosphatase; Ets-1 Z v-ets erythroblastosis virus E26
HIF Z hypoxia-inducible factor; KLF Z Kru¨ppel-like factor;
r.
Figure 3 Biological functions of HIF-1a-regulated miRNA. CULZ cullin; DAPKZ death-associated protein kinase; DUSPZ dual-
specificity phosphatase; EFNAZ ephrin-A3; Ets-1Z v-ets erythroblastosis virus E26 oncogene homolog 1; FGFRZ fibroblast growth
factor receptor; HIF Z hypoxia-inducible factor; KLF Z Kru¨ppel-like factor; PHD Z prolyl hydroxylase; VEGF Z vascular endo-
thelial growth factor.
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angiogenesis. Furthermore, they also proved an elusive
mechanism that miR-424 expression was regulated by C/
EBP-a/RUNX-1-mediated transactivation. This finding in-
dicates that not only HIF-1a regulates the transcription of
miRNAs, but the stability of HIF-1a protein is also affected
by the expression of some miRNAs. This finding is very
interesting because it shows that miR-424 is a critical
mediator affecting the proteasome degradation pathway
and thus increasing HIF-1a expression under hypoxia. Be-
sides, this finding also shows that miR-424 is physiologically
upregulated in tissues undergoing vascular remodeling and
angiogenesis, which are important factors for cancer
malignancy.
MiR-20a
It is reported that constitutive activation of extracellular
signal-regulated kinase (ERK) signaling pathway is associ-
ated with tumor progression in many cancers such as colon,
ovary, pancreas, and lung cancers.79e81 In addition, it is
demonstrated that activation of ERK signaling in cancer
cells also results in drug resistance.82e84 Dual-specificity
phosphatases (DUSPs) comprise a group of phosphatases
that regulate MAPKs negatively by dephosphorylating
phosphothreonine and phosphotyrosine residues.85 DUSPs
are classified into three groups according to their subcel-
lular localization. Dual-specificity phosphatase 2 (DUSP2)
belongs to class I DUSPs, which dephosphorylates nuclear
substrates and inactivates ERK activity predominantly.86,87
It has been demonstrated that the expression of DUSP2 issuppressed under hypoxia, resulting in prolonged ERK
activation, which in turn elevates malignancy and drug
resistance in human cancers.34 Another study reported that
DUSP2 was a target of miR-20a, and miR-20a was tran-
scriptionally upregulated by HIF-1a under hypoxia.60 It was
also found that some genes downstream of ERK, such as
EGR-1, MDR-1, CYP61, and osteopontin, were induced
under hypoxia in an miR-20a-dependent manner.60 Notably,
EGR-1, MDR-1, CYR-61, and osteopontin have been reported
to be involved in tumor aggression and drug resistance.88,89
The oncogenic function of miR-20a in a variety of cancer
types was reported in many studies.90e93 MiR-20a was
upregulated significantly in colorectal cancers,94 and an
increased miR-20a level in colorectal cancers has been
found to contribute to chemotherapy resistance.95 The
finding that hypoxia-induced miR-20a suppresses DUSP2
expression, thereby activating ERK activation and inducing
some angiogenesis-related genes, indicates the important
role of miR-20a under hypoxia and its potential influence on
malignancy and drug resistance in cancer cells.
MiR-210
MiR-210 is the most well-known HRM and a versatile miRNA
that regulates many aspects of hypoxia pathways, in both
physiological and malignant conditions.61 MiR-210 is
induced under hypoxia in a wide range of primary and
transformed cells.61,62 HIF-1a has been demonstrated to
recognize HRE on the miR-210 promoter.63 When comparing
miR-210 core promoters across species, this HRE site is
highly conserved, indicating that the regulation of miR-210
Hypoxia-mediated miRNA in drug resistance 7expression by hypoxia is a universal phenomenon in these
species. In addition, the presence of HRE in the miR-210
promoter region also suggests that the expression level of
miR-210 may be a reflection of HIF activity. The upregula-
tion of miR-210 in solid tumors is associated negatively with
the prognosis, indicating that the target genes affected by
miR-210 have functional impact on tumor malignancy and
drug resistance. Recently, a number of miR-210 targets
have been reported, whose functional roles include mito-
chondrial metabolism, angiogenesis, DNA repair, and cell
survival.
It was reported that miR-210 decreases mitochondrial
function and upregulates glycolysis.64 From the identified
functions influenced by miR-210, we know that intervention
of miR-210 has a potential in therapeutic application.
Recent studies revealed that suppression of miR-210 can
sensitize tumor cells to radiation in a variety of cancers by
inhibiting proliferation and promoting apoptosis.65,66 Based
on the identified target genes of miR-210 and the finding
that expression of miR-210 is elevated in a variety of solid
tumors, we speculate that targeting miR-210 may create a
new avenue for more effective cancer treatment.
MiR-200b
MiR-200b was reported to be upregulated during ischemic
preconditioning and PHD2, the enzyme activity of which
was inhibited under hypoxia, was found to be targeted by
miR-200b.67 This finding shows an additional example that
miRNAs affect HIF-1a activity by targeting PHD2 and further
influence angiogenesis. Notably, in another study by Meng
et al,68 they found that overexpression of miR-200b con-
tributes to chemoresistance in cholangiocarcinoma by
inhibiting PTPN12. Based on the finding of miR-200b in
regulating HIF-1a and its mentioned role in chemoresponse,
hypoxia-regulated miR-200b in drug resistance in cancer
cells is worth further investigation.
However, a recent study showed that miR-200b over-
expression in human microvascular endothelial cells sup-
pressed the angiogenic response. In the study published by
Chan et al,69 they found that v-ets erythroblastosis virus
E26 oncogene homolog 1 (Ets-1), a transcription factor that
controls the expression of genes related to angiogenesis, is
a novel target of miR-200b. In human microvascular endo-
thelial cells, the expression of miR-200b was significantly
inhibited under hypoxia, allowing Ets-1 upregulation to
promote angiogenesis. This evidence explains that one
miRNA may have opposite response to hypoxia according to
the cellular context, duration, and severity of oxygen
deprivation thus exert different biological functions by
affecting diverse target genes.
MiR-15b and miR-16
Angiogenesis is an important trait, by which the hypoxic
region of cancer cells can acquire oxygen and nutrients
again. This neovascular network allows tumor growth and
metastasis.96 VEGF, the most well-studied angiogenic fac-
tor, is upregulated under hypoxia.31 As reported in the
study published by Hua et al,70 miR-15b and miR-16 in
human nasopharyngeal carcinoma cells weredownregulated by hypoxia treatment, and both miR-15b
and miR-16 were found to have repressive effects on
VEGF under normoxia. Dejean et al71 found that miR-16 was
downregulated in an HIF-1a-dependent manner, and the
expressions of miR-16 and VEGF presented an inverse cor-
relation in anaplastic large cell lymphomas. Interestingly,
downregulation of miR-15b and miR-16 was found to result
in drug resistance in gastric cancer cells, and this resistance
was ascribed to elevated BCL-2, a target of miR-15b and
miR-16.72 Thus, downregulation of miR-15b and miR-16
under hypoxia implies the potential mechanism that regu-
lates the drug resistance induced by hypoxia.
MiR-100
Fibroblast growth factor receptor 3 (FGFR3), one of four
members of the FGFR family of receptor tyrosine kinases, is
of paramount importance in the pathogenesis of bladder
cancer.97 Signals elicited by FGFRs lead to the activation of
multiple intracellular signaling pathways such as MAPK and
PI3K signaling cascades.98 Blick and colleagues73 found that
FGFR3 is a target of miR-100, and the upregulation of FGFR3
is mediated through HIF-1a-dependent transcriptional
upregulation and suppression of miR-100, leading to
elevation of FGFR3. This finding provides additional evi-
dence that deregulated miRNA under hypoxia affects pro-
liferation signals of cancer cells.
MiR-199a
Differentially expressed miRNA in the heart revealed that
miR-199a was reduced to an undetectable level during
cardiac ischemia. Functional analysis indicates that this
reduction is required for upregulation of hypoxia-induced
apoptotic genes. Computational prediction and experi-
mental evidence show that HIF-1a is a direct target of miR-
199a. Knockdown of miR-199a under normoxia results in the
upregulation of HIF-1a, suggesting that it might be associ-
ated with the inhibition or downregulation of PHD2. Sur-
prisingly, PHD2 was found to be reduced in miR-199a
knockdown cells and this reduction was reversed by over-
expression of miR-199a. Further analysis showed that Sir-
tuin 1, a class III histone deacetylase that is responsible for
downregulating PHD2, is also a target of miR-199a. This
finding demonstrated that miR-199a regulates two key
molecules that are functionally linked under hypoxia.74 In
addition to this finding, it was demonstrated that the
reduction in miR-199a levels is highly associated with the
progression of non-small-cell lung cancer, and this effect is
also related to the corresponding upregulation of HIF-1a.75
Interaction among miRNAs in cancer
development
As miRNAs influence many biological processes such as
human diseases, maintaining accurate levels of miRNAs is
important. Regulation of miRNA biogenesis and turnover
occur both transcriptionally and post-transcriptionally.99
Numerous Pol II-associated transcription factors are
involved in the transcriptional control of miRNA genes. For
8 W.-L. Liao et al.example, tumor suppressor p53 activates the miR-34 fam-
ily,100 whereas the proto-oncogene c-Myc transactivates or
represses a number of miRNAs that are involved in the cell
cycle and apoptosis.77,101,102
Post-transcriptional regulation of miRNAs occurs at
various steps, including processing, maturation, stabiliza-
tion, and degradation of miRNAs.103 Although many regu-
latory factors involved in this processing are still unclear, it
is plausible that some RNA-binding proteins influence
miRNA processing through specific interactions. The let-7
miRNA is an example indicating that its expression
pattern is controlled post-transcriptionally. Experimental
evidence shows that the primary transcript of let-7 is
expressed in both undifferentiated and differentiated em-
bryonic stem cells, whereas mature let-7 is detected only in
differentiated cells; similar post-transcriptional inhibition
of let-7 also takes place in tumor cells.104,105 Recent studies
have shown that LIN28, an RNA-binding protein, is respon-
sible for the suppression of let-7 biogenesis, through
interference with Dicer processing106 and terminal uridy-
lation of pre-let-7.107
Although the possibility of miRNAs regulating other
miRNAs has been postulated, little evidence exists in the
literature. Chen et al108 found that miR-107 can interact
directly with let-7 and promote let-7 degradation. Let-7 has
been reported to suppress proliferation by targeting the
oncogene Ras109 In their study, they also found that miR-107
was highly expressed in patients with advanced breast
cancer, with an inverse correlation with the levels of let-7.
Functional assays demonstrated that downregulation of the
tumor suppressor miRNA let-7 is important for miR-107-
mediated tumorigenesis. The interaction among miR-107
and let-7 provides an explanation for the acceleration of
tumor progression by miR-107. Besides, the authors also
indicated that the two miRNAs have reciprocal suppression
to each other, suggesting that the interaction among miR-
NAs should be in a balanced situation under normal condi-
tion, but the balance is disturbed by cancer development.
This study shows that miRNA expression can be controlled
post-transcriptionally by interaction with other miRNAs.Conclusion and future perspectives
A comprehensive understanding of the roles of miRNAs in
tumor malignancy and chemoresistance in hypoxia requires
a complete knowledge of the target genes that influence
hypoxia-induced cellular activities. Although identification
of new targets of HRMs is a bottleneck in the miRNA field,
more and more targets can be identified in the future with
the application of screening techniques and experimental
evidence.
Due to the pervasive failure of traditional chemothera-
peutic drugs in treating hypoxic cancers, new strategies
have been developed. MiRNAs should be new considerations
in future clinical assays to help guide therapeutic decisions
or even to be valuable therapeutic tools for specific can-
cers. The concept of therapeutic modulation of miRNAs is
to design molecules that can inhibit or mimic mature miR-
NAs effectively, in order to achieve losses or gains of miRNA
function, respectively. Based on this idea, targeting miRNAs
overexpressed in cancer or re-expressing thosedownregulated in cancer represents an optional approach.
Currently, antisense oligonucleotides (ASOs) complemen-
tary to mature miRNAs are designed to block miRNA func-
tion in the miRNP silencing complex; this has become an
effective technology for controlling miRNA expression
experimentally and/or therapeutically.110 In order to in-
crease their stability, chemical modification is applied to
ASOs to prevent nuclease degradation. Evidence has shown
that ASO-mediated miR-21 inhibition in prostate cancer
increases cell sensitivity to apoptosis and inhibits cell
motility and invasion,111 whereas transfection of breast
cancer cells with anti-miR-21 oligonucleotides show sup-
pressed cell proliferation.112 In addition to ASOs, which
contain only one binding site for the target miRNA, a
different class of miRNA inhibitors containing multiple
binding sites per molecule, named miRNA sponges, was
developed.113 In breast cancer, an miR-9 sponge trapping
overexpresses miR-9 related to cancer metastasis, thereby
effectively reducing invasiveness of tumor cells,114 and an
miR-17-92 cluster sponge significantly inhibits the prolifer-
ation of cultured B-cell lymphoma cells.115
MiRNA mimics and plasmid or virally encoded miRNA
constructs have widely been used as replacement therapies
for the downregulated tumor suppressor miRNA. It was re-
ported that delivery of let-7 miRNA intratumorally in a
mouse model with non-small-cell lung cancer led to a
reduction of tumor burden.116 Another deregulated miRNA
associated with several cancers is miR-34. Recent studies
show that re-expression of miR-34 in human colon cancer
cells inhibits cell proliferation significantly.117
The above evidence shows that miRNAs are promising
potential therapeutic targets, but their challenges
regarding stability, safety, and effective delivery to specific
sites are of concern. Future clinical trials should focus on
improving the safety and efficacy of miRNA-based anti-
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